Lixte expands NKI/Oncode collaboration to study LB-100 + immunotherapy in additional cancers

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Amendment 2 extends the Development Collaboration Agreement for two more years.
New focus: drug synergies of LB-100 with immunotherapy plus synthetic lethal combinations in more cancer types.
Prior two-year collaboration successfully identified LB-100 combinations for colon cancer.
Parties include Netherlands Cancer Institute and Oncode Institute, with Prof. René Bernards on Lixte's board.
No financial terms or milestones disclosed in the agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

LIXTE BIOTECHNOLOGY HOLDINGS, INC. amended Development Collaboration Agreement Amendment 2 with Netherlands Cancer Institute (NKI) and Oncode Institute valued at Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years (effective 2023-10-13).

Action: amendment
Agreement: collaboration
Counterparty: Netherlands Cancer Institute (NKI) and Oncode Institute
Value: Amendment expands collaboration to study LB-100 with immunotherapy, extends agreement for two years
Effective: 2023-10-13

Exact text from the filing

On October 13, 2023, the parties signed an amendment (“Amendment 2”) to expand the collaboration to study drug synergies of the Company’s lead compound, LB-100, with immunotherapy in various cancers. Under Amendment 2, the parties will seek to find synthetic lethal combinations in additional cancer types. Amendment 2 also extends the Collaboration Agreement for an additional two years.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-037533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.